Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Electro-Optical Sciences has completed patient accrual in the MelaFind pivotal trial. MelaFind is said to be a non-invasive, point-of-care instrument designed and developed by the company to assist in the early diagnosis of melanoma.
Subscribe to our email newsletter
The blinded pivotal trial, which will serve as the basis for the company’s pre-market approval (PMA) application with the FDA, was conducted at seven centers in the US.
Investigators used the MelaFind system to evaluate over 1,800 suspicious lesions from over 1,300 patients. All the suspicious lesions were subsequently biopsied and sent for dermatohistopathologic analysis. Results of the pivotal trial are anticipated in the fourth quarter of 2008, with PMA filing to follow.
Joseph Gulfo, president and CEO of Electro-Optical Sciences (EOS), said: “This represents a significant milestone for the company in our quest to improve early melanoma detection.”